BioLineRx (NASDAQ:BLRX) Now Covered by Analysts at StockNews.com

StockNews.com assumed coverage on shares of BioLineRx (NASDAQ:BLRX) in a research report released on Sunday morning. The firm issued a hold rating on the biotechnology company’s stock.

Separately, HC Wainwright reaffirmed a “buy” rating and issued a $21.00 target price on shares of BioLineRx in a research report on Wednesday, November 6th.

BioLineRx Price Performance

BLRX stock opened at $0.28 on Friday. BioLineRx has a 52-week low of $0.26 and a 52-week high of $1.89. The stock’s fifty day simple moving average is $0.49 and its 200-day simple moving average is $0.61. The company has a quick ratio of 1.49, a current ratio of 1.61 and a debt-to-equity ratio of 1.34. The stock has a market capitalization of $22.23 million, a price-to-earnings ratio of -0.62 and a beta of 1.48.

Institutional Inflows and Outflows

Several hedge funds have recently added to or reduced their stakes in BLRX. CVI Holdings LLC purchased a new stake in shares of BioLineRx during the second quarter worth about $462,000. PVG Asset Management Corp bought a new stake in BioLineRx during the second quarter worth approximately $70,000. Finally, Atria Investments Inc raised its holdings in BioLineRx by 27.9% during the third quarter. Atria Investments Inc now owns 133,974 shares of the biotechnology company’s stock worth $72,000 after purchasing an additional 29,193 shares in the last quarter. 1.56% of the stock is owned by hedge funds and other institutional investors.

About BioLineRx

BioLineRx Ltd., a commercial stage biopharmaceutical company, develops and commercializes therapeutics for oncology and rare diseases. The company's pipeline includes APHEXDA (motixafortide), a peptide that is in Phase 1 clinical trial for the treatment of sickle cell disease, and Phase 2b clinical trial for the treatment of pancreatic cancer, as well as completed Phase 3 clinical trial for the treatment of multiple myeloma.